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22.5 days; p = 0.35).  Conclusion: TAVI is a safe procedure in 
patients on chronic hemodialysis. Until new data become 
available, we find no compelling reason to refuse these pa-
tients TAVI.  Copyright © 2012 S. Karger AG, Basel 
 Background/Aims 
 Valvular heart disease is common in patients with 
end-stage renal disease (ESRD). In patients on chronic 
hemodialysis, aortic valve calcification is present in 25–
55% and it occurs 10–20 years earlier than in the general 
population  [1–9] . Pathophysiology and the rate of pro-
gression of cardiac valvular calcification in patients with 
ESRD appear to be different from those in the general 
population, with secondary hyperparathyroidism being 
one of the most important predisposing factors. 
 Symptomatic aortic stenosis carries a poor prognosis 
with 1- and 5-year survival of 60 and 32%, respectively 
 [10] , for nonsurgically managed patients. Aortic valve re-
placement is the only way to improve survival, but surgi-
cal aortic valve replacement (SAVR) has an estimated op-
erative mortality of 4% in the general population  [11] . 
One third of patients with severe valvular heart disease 
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 Abstract 
 Background/Aims: Transcatheter aortic valve implantation 
(TAVI) has emerged as a new therapeutic option for high-risk 
patients. However, dialysis patients were excluded from all 
previous studies. The aim of this study is to compare the out-
comes of TAVI for dialysis patients with those for patients 
with chronic kidney disease (CKD) stages 3 and 4 and to com-
pare TAVI with open surgery in dialysis patients.  Methods: 
Part I: comparison of 10 patients on chronic hemodialysis 
with 116 patients with non-dialysis-dependent CKD under-
going TAVI. Part II: comparison of transcatheter (n = 15) with 
open surgical (n = 24) aortic valve replacement in dialysis 
patients.  Results: Part I: dialysis patients were significantly 
younger (72.3 vs. 82.0 years; p  ! 0.01). Hospital stay was sig-
nificantly longer in dialysis patients (21.8 vs. 12.1 days; p = 
0.01). Overall 30-day mortality was 3.17%, with no deaths 
among dialysis patients. Six-month survival rates were simi-
lar (log-rank p = 0.935). Part II: patient age was comparable 
(66.5 vs. 69.5 years; p = 0.42). Patients in the surgical group 
tended to stay longer in hospital than TAVI patients (29.5 vs. 
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do not undergo surgery, however, because of advanced 
age or multiple comorbidities including chronic kidney 
disease (CKD)  [12] .
 Since April 2002 transcatheter aortic valve implanta-
tion (TAVI) has emerged as a new therapeutic option for 
high-risk patients  [13] . Meanwhile, several thousand such 
devices have been implanted worldwide and several stud-
ies on safety and outcomes of TAVI have been performed. 
TAVI, when compared with standard medical therapy, 
significantly reduces mortality in patients with severe 
aortic stenosis who are not suitable for surgery  [14] . Up to 
50% of patients undergoing TAVI in large studies had 
preexisting CKD  [15] . However, patients with ESRD on 
chronic hemodialysis were excluded from all previous 
studies.
 The aim of this study is to report the first preliminary 
experiences of patients on chronic hemodialysis under-
going TAVI. In the first part, outcomes of patients on 
chronic hemodialysis are compared with patients with 
CKD stages 3 and 4 undergoing TAVI at our center. In the 
second part, outcomes of open SAVR are compared with 
percutaneous aortic valve replacement in patients on 
chronic hemodialysis using a standardized question-
naire.
 Patients and Methods 
 Part I 
 From November 2007 to May 2010, 200 patients with severe 
aortic stenosis not considered suitable for SAVR underwent TAVI 
at our institution. Patients were included in cases of symptomatic 
high-grade aortic stenosis defined by transthoracic echocardiog-
raphy (aortic valve area  ! 0.8 cm 2 ). In addition, at least one of the 
following inclusion criteria was mandatory: logistic European 
System for Cardiac Operative Risk Evaluation (logEuroSCORE) 
 1 15, age  1 80 years, patient refusing conventional surgery or life 
expectancy less than 5 years due to malignant disease. CKD was 
defined as a preprocedural eGFR  ! 60 ml/min, equivalent to a 
CKD stage  6 3 according to K/DOQI. All patients provided 
signed informed consent for the procedure. Diagnostic heart 
catheterization was conducted prior to TAVI. In cases of hemo-
dynamically relevant coronary artery disease, stent implantation 
was performed.
 Aortic annular dimension and ascending aortic diameter were 
assessed by CT scan. In all patients, TAVI was performed in the 
catheterization laboratory using local anesthesia and additional 
intravenous analgesia when necessary. Vascular access was ob-
tained through the common femoral artery in all patients. A 
transcutaneous suture system was placed into the right or left 
common femoral artery. The CoreValve prosthesis (CoreValve 
Inc., Irvine, Calif., USA, since 2009: Medtronic, Meerbusch, Ger-
many) was used in all patients. It consists of a trileaflet biopros-
thetic pericardial tissue valve that is mounted and sutured in a 
self-expanding nitinol stent. 
 The logEuroSCORE was used as a risk calculator to estimate 
the probability of death. The primary endpoint was 30-day mor-
tality, defined as death for any reason within 30 days after the 
intervention.
 Part II 
 An anonymized, standardized questionnaire concerning aor-
tic valve replacement was developed and sent to 55 hemodialysis 
centers in southern Germany (Bavaria). All patients who under-
went aortic valve replacement during 2005 and 2010 and who were 
on chronic dialysis at the time of intervention were included. All 
modalities of replacement (open surgery, transfemoral, transapi-
cal, transaxillary) were included, resulting in a study population 
of 39 patients. The objectives of the questionnaire were gender, 
age at intervention, accompanying coronary intervention, length 
of hospital stay, mode and duration of dialysis and underlying re-
nal disease. Patients were questioned on the presence of the fol-
lowing comorbidities: coronary heart disease, atrial fibrillation, 
arterial hypertension, chronic obstructive pulmonary disease, di-
abetes and peripheral artery disease. The study was approved by 
the institutional ethical review committee.
 Statistical Analysis 
 Continuous variables are expressed as means with standard 
deviations of the mean (SD). Categorical variables are expressed 
as total counts and column percentages. Differences in variables 
were evaluated by using Student’s t test (normal distributed data) 
for continuous variables and Fisher’s exact test for categorical 
variables. Results were considered statistically significant if p  ! 
0.05. Survival curves were generated using Kaplan-Meier meth-
ods and compared using a log-rank test. Statistical analyses were 
performed using SPSS, version 19.
 Results 
 Part I 
 Baseline demographic and clinical characteristics of 
dialysis patients and patients with non-dialysis-depen-
dent CKD undergoing TAVI at our center are reported in 
 table 1 . 
 Preprocedural eGFR was less than 60 ml/min in 126 
patients, consisting of 116 patients with non-dialysis-de-
pendent CKD with a mean eGFR of 43.1  8 11.3 ml/min 
and 10 patients with ESRD on chronic hemodialysis. 
There were no significant differences in the following 
preexisting comorbidities: coronary heart disease, atrial 
fibrillation, arterial hypertension, chronic obstructive 
pulmonary disease, diabetes and peripheral artery dis-
ease. The logEuroSCORE as a risk calculator to estimate 
the probability of death was worse in the dialysis patients, 
but without statistical significance (32.6  8 13.9 vs. 25.3 
 8 13.6%; p = 0.16). Apart from kidney function, the only 
preprocedural significant difference was patient age at 
the time of intervention. Dialysis patients were signifi-
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cantly younger than patients not in need of dialysis (72.3 
 8 6.4 vs. 82.0  8 5.6 years; p  ! 0.01). 
 There were no significant differences between dialy-
sis patients and patients in the CKD group with respect 
to stroke, bleeding or vascular access problems: stroke 
0% (0/10) versus 0.8% (1/126; p = 0.77), major bleeding 
0% (0/10) versus 8.7% (11/126; p = 0.31), puncture site 
hematoma requiring operation 10% (1/10) versus 1.6% 
(2/126; p = 0.43) and development of a false aneurysm at 
the puncture site 20% (2/10) versus 8.7% (11/126; p = 
0.30).
 The mean length of hospital stay was 12.9  8 8.75 days. 
Patients on chronic hemodialysis stayed significantly 
longer in hospital than patients in the CKD group (21.8 
 8 11.9 vs. 12.1  8 8.0 days; p = 0.01). 
 For calculation of overall mortality, all 126 patients 
were considered. Overall 30-day mortality was 3.17% 
(4/126). 30-day mortality in the CKD group was 3.45% 
(4/116). There were no deaths within 30 days among pa-
tients who were on chronic hemodialysis. Survival rates 
6 months after intervention were similar in both groups 
(log-rank p = 0.935), with a survival of 80% in the dialysis 
group. Kaplan-Meier survival curves of the two groups 
are shown in  figure 1 . 
 Part II 
 Questionnaires were sent back by 26 of the 55 hemo-
dialysis centers with complete data collection of 39 dialy-
sis patients. Baseline demographic and clinical character-
istics of the 39 dialysis patients after TAVI and SAVR are 
reported in  table 2 . 
 61.5% of patients (24/39) underwent open surgery 
and transcutaneous aortic valve replacement was per-
Table 1.  Baseline demographics: part I
Dialysis
patients
(n = 10)
Nondialysis
patients
(n = 116)
p
value
Demographic data
Age, years 72.386.4 82.085.6 <0.01
Male 80 (8/10) 40.5 (47/116) 0.21
Clinical data
EuroSCORE, % 33814 25814 0.16
Hypertension 90 (9/10) 85 (98/116) 1
Diabetes mellitus 50 (5/10) 35 (41/116) 0.46
Coronary artery disease 78 (7/9) 54 (63/116) 0.30
Peripheral vascular disease 38 (3/8) 14 (16/116) 0.10
COPD 11 (1/9) 22 (25/116) 0.68
Atrial fibrillation 56 (5/9) 38 (44/116) 0.31
B aseline demographic and clinical characteristics of dialysis pa-
tients (n = 10) and patients with non-dialysis-dependent CKD (n = 
116) undergoing TAVI. Single-center data from our department (n = 
126). Continuous variables are expressed as means with SD of the 
mean. Categorical variables are expressed as percentages and total 
counts (total counts differ according to data collection).
Table 2.  Baseline demographics: part II
SAVR
(n = 24)
TAVI
(n = 15)
p
value
Demographic data
Age, years 66.5811.1 69.5811.1 0.42
Male 79 (19/24) 73 (11/15) 0.71
Clinical data
Hypertension 88 (21/24) 87 (13/15) 1
Diabetes mellitus 26 (6/23) 40 (5/15) 0.48
Coronary artery disease 68 (15/22) 86 (12/14) 0.43
Peripheral vascular disease 30 (7/23) 33 (4/12) 1
COPD 13 (3/23) 14 (2/14) 1
Atrial fibrillation 35 (8/23) 46 (6/13) 0.72
B aseline demographic and clinical characteristics of dialysis pa-
tients after TAVI (n = 15) and SAVR (n = 24). Data retrieved from 
an anonymized, standardized questionnaire sent to 55 hemodialysis 
centers (n = 39). Continuous variables are expressed as means with 
SD of the mean. Categorical variables are expressed as percentages 
and total counts (total counts differ according to data collection).
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 Fig. 1. Kaplan-Meier survival curves of dialysis patients and pa-
tients with non-dialysis-dependent CKD undergoing TAVI. Sur-
vival rates are similar in both groups (log-rank p = 0.935) with
no deaths within 30 days after intervention and a survival rate of 
80% after 6 months in the dialysis group. 
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formed in 38.5% (15/39): 60% (9/15) transfemoral, 20% 
(3/15) transapical and 20% (3/15) transaxillary. In pa-
tients with SAVR, 83.3% (20/24) received bioprosthetic 
valves and 16.6% (4/24) mechanical prosthetic valves. 
There were no significant differences in the following 
preexisting comorbidities: coronary heart disease, atrial 
fibrillation, arterial hypertension, chronic obstructive 
pulmonary disease, diabetes and peripheral vascular 
disease. The preprocedural patient age in the SAVR and 
TAVI groups was similar (66.5  8 11.1 vs. 69.5  8 11.1 
years; p = 0.42).
 The mean length of hospital stay was 26.4  8 21.7 days. 
Patients undergoing SAVR stayed longer in hospital than 
patients undergoing TAVI, but this trend was not signifi-
cant (29.5  8 25.8 vs. 22.5  8 13.1 days; p = 0.35). 
 There are no solid survival data from the SAVR group, 
as questionnaires were mainly retrieved from living pa-
tients still performing hemodialysis in the corresponding 
centers.
 Discussion 
 The prevalence of aortic valve calcification is higher in 
patients with CKD than in the general population and 
dialysis has been proposed to be an independent risk fac-
tor for aortic valve calcification  [1–9] . Different studies on 
SAVR in dialysis patients have been performed  [16–18] , 
showing an increased surgical risk in these patients. The 
largest study of 5,858 dialysis patients undergoing surgi-
cal valve replacement found an in-hospital mortality rate 
of 20.7%  [18] . Apart from a high general morbidity, pos-
sible reasons might be the need for general anesthesia and 
problems in perioperative fluid management and dialy-
sis. Since the number of patients with CKD is increasing 
and life expectancy is extending, the incidence of dialysis 
patients requiring aortic valve replacement is expected to 
increase in the future. 
 TAVI, as a new interventional procedure, might be a 
suitable alternative for these high-risk patients. A first 
randomized trial by Smith et al.  [19] demonstrated that 
TAVI and SAVR are associated with a similar survival at 
1 year in high-risk patients with severe aortic stenosis. 
Unfortunately, this study excluded patients with severe 
renal insufficiency and there are no data at all on TAVI 
in dialysis patients. 
 In this study, we report the first experiences of a series 
of patients on chronic hemodialysis undergoing TAVI at 
our center (n = 10). Moreover, we analyzed TAVI in com-
parison to SAVR in dialysis patients (n = 39) using an 
anonymized, standardized questionnaire, sent to 55 di-
alysis centers in southern Germany (Bavaria).
 Results from our questionnaire showed a similar pre-
procedural patient age of dialysis patients in the TAVI and 
in the SAVR group (69.5 vs. 66.5 years; p = 0.42), but on 
the other hand, dialysis patients were significantly young-
er than patients not in need of dialysis undergoing TAVI 
at our center (72.3 vs. 82.0 years; p  ! 0.01). One potential 
reason might be the faster progression rate of cardiac val-
vular calcification in patients with ESRD compared to the 
normal population  [1–9] . The higher Euro SCORE reflects 
the poor preinterventional clinical status of these patients, 
making them not suitable for open surgery. 
 The length of hospital stay after TAVI is significantly 
longer in patients on chronic hemodialysis compared to 
nondialysis patients (21.8 vs. 12.1 days; p = 0.031). Once 
more, this illustrates the poor clinical status of this pa-
tient group, complicating postinterventional convales-
cence. However, according to our questionnaire, dialysis 
patients still tend to leave hospital earlier after TAVI than 
after SAVR (22.5 days vs. 29.5 days; p = 0.35). This is cer-
tainly a consequence of the less-invasive procedure and
is in agreement with the data of Smith et al.  [19] , who al-
so reported a shorter index hospitalization in the TAVI 
group. Accelerating discharge from hospital may not only 
reduce cost but, more importantly, may be of great ben-
efit for the improved rehabilitation of these severely ill 
patients.
 Comparing patients on chronic hemodialysis with 
nondialysis patients undergoing TAVI, we found no dif-
ference in the 30-day or 6-month mortality rates, respec-
tively. Overall 30-day mortality was 3.17%, with no deaths 
within 30 days among dialysis patients who underwent 
TAVI at our center. These preliminary data derived from 
a first small cohort suggest that dialysis patients undergo-
ing TAVI do not have an increased risk for in-hospital 
mortality compared to other patients. Survival rates for 
dialysis patients 6 months after intervention were similar 
to those patients not in need of dialysis (log rank p = 
0.935). 
 Our first experiences show that TAVI can be per-
formed safely in dialysis patients, whereas open surgery 
is still associated with a substantial rate of in-hospital 
mortality up to 20.7%  [18] . In addition, one has to assume 
that patients who undergo TAVI do not qualify for SAVR 
due to higher age and more severe comorbidities, thus 
making an even worse outcome very likely for such pa-
tients. Due to the small population size, however, it is dif-
ficult to compare our results with historical outcomes
after surgical aortic valve repair.
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 In summary, TAVI seems to be a safe procedure in
dialysis patients. Nevertheless, much larger studies are 
needed to evaluate the long-term outcome of TAVI in 
these patients and to compare this new interventional 
technique with the traditional open-valve surgery in this 
growing patient population. Until new data become avail-
able, we find no compelling reason to refuse TAVI to pa-
tients on chronic hemodialysis. TAVI can be safely ap-
plied in dialysis as well as in nondialysis patients, who are 
not suitable for open surgery. A possible superiority of 
TAVI for patients on dialysis compared to open surgery 
should be the subject of future studies.
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